PHARMAC proposal to decline inactive funding applications: Ingenol mebutate for solar (actinic) keratosis lesions
October 1, 2020
PHARMAC have identified inactive funding applications for a number of different medicines that they are proposing to decline. Those that relate to skin cancer are ingenol mebutate for solar (actinic) keratosis lesions.
For each medicine:
- clinical advice on the application was received at least 12 months ago.
- assessment has determined that the medicine would provide no additional benefits over treatments already funded
- from subsequent assessment including communications with applicants and suppliers, it has been determined that the price of the medicine would not be the same, or less expensive than, the funded alternative treatment.
PHARMAC are seeking feedback on their proposal.
Consultation closes at 5pm Friday 30 October 2020 and feedback can be emailed to applicationfeedback@pharmac.govt.nz.